/주식/MBRX
MBRX

MBRX

USD

Moleculin Biotech Inc. Common Stock

$0.497+0.014 (2.836%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$0.483

고가

$0.502

저가

$0.470

거래량

2.28M

기업 기본 정보

시가총액

24.6M

산업

생명공학

국가

United States

거래 통계

평균 거래량

4.00M

거래소

NCM

통화

USD

52주 범위

저가 $0.25현재가 $0.497고가 $3.65

관련 뉴스

GlobeNewswire

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting

HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat

더 보기
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting
GlobeNewswire

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat

더 보기
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
GlobeNewswire

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON,

더 보기
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
PR Newswire

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...

더 보기
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions